Introduction:Metformin(MET)has been shown in animal models and diabetic patients with depression to have antidepressant effects.MET is gaining attraction as a treatment for depression;nevertheless,a comprehensive revi...Introduction:Metformin(MET)has been shown in animal models and diabetic patients with depression to have antidepressant effects.MET is gaining attraction as a treatment for depression;nevertheless,a comprehensive review and evaluation are essential.The primary objective of this review article is to evaluate metformin's effectiveness and safety in the treatment of depression.Methods and analysis:From inception,a wide-ranging survey of the literature will be conducted to categorize possibly suitable studies from online databanks such as the Wan-Fang Database,Chinese Scientific Journal Database(VIP database),Chinese Biomedical Literature Database(CBM),China National Knowledge Infrastructure(CNKI),Traditional Chinese Medicine databases,the Web of Science,EMBASE,PubMed,and the Cochrane Central Register of Controlled Trials(CENTRAL).For this search,no linguistic constraints will be applied.Only randomized controlled trials will be considered,and each study's bias risk will be assessed using the Cochrane Risk of Bias tool.The primary outcome measures will be self-rating scales or clinician-rated scales.Depression remission and quality-of-life indices will be secondary outcomes.The evidence quality for each study will be assessed by grading the review process,development,and recommendations.Ethics and dissemination:The primary data will not be collected in this review;therefore,no ethical consent is required.The results of this methodical review will be available in a peer-reviewed scientific publication and will be made freely accessible.PROSPERO registration number CRD42021286394 Strengths and limitations of this study:This protocol will ensures that the methodologies and processes employed are transparent,allows for peer review,and avoids the risk of bias and duplication.Meta-analyses will not be used as a method of quantitative synthesis.This review study will map the literature on randomized controlled trials of metformin for depression treatment,assess the scope and significance of future systematic reviews on the topic,and identify research gaps and limitations of this study.展开更多
基金supported by Tianjin Science and Technology Plan Project Science and Technology Major Project and Engineering Chronic Disease Prevention and Control Science and Technology Major Project(grant number 17ZXMFSY00100)Capability Enhancement Project for Key Disciplines of Traditional Chinese Medicine(grant number 2018ZDXK006).
文摘Introduction:Metformin(MET)has been shown in animal models and diabetic patients with depression to have antidepressant effects.MET is gaining attraction as a treatment for depression;nevertheless,a comprehensive review and evaluation are essential.The primary objective of this review article is to evaluate metformin's effectiveness and safety in the treatment of depression.Methods and analysis:From inception,a wide-ranging survey of the literature will be conducted to categorize possibly suitable studies from online databanks such as the Wan-Fang Database,Chinese Scientific Journal Database(VIP database),Chinese Biomedical Literature Database(CBM),China National Knowledge Infrastructure(CNKI),Traditional Chinese Medicine databases,the Web of Science,EMBASE,PubMed,and the Cochrane Central Register of Controlled Trials(CENTRAL).For this search,no linguistic constraints will be applied.Only randomized controlled trials will be considered,and each study's bias risk will be assessed using the Cochrane Risk of Bias tool.The primary outcome measures will be self-rating scales or clinician-rated scales.Depression remission and quality-of-life indices will be secondary outcomes.The evidence quality for each study will be assessed by grading the review process,development,and recommendations.Ethics and dissemination:The primary data will not be collected in this review;therefore,no ethical consent is required.The results of this methodical review will be available in a peer-reviewed scientific publication and will be made freely accessible.PROSPERO registration number CRD42021286394 Strengths and limitations of this study:This protocol will ensures that the methodologies and processes employed are transparent,allows for peer review,and avoids the risk of bias and duplication.Meta-analyses will not be used as a method of quantitative synthesis.This review study will map the literature on randomized controlled trials of metformin for depression treatment,assess the scope and significance of future systematic reviews on the topic,and identify research gaps and limitations of this study.
